Plain-English translation of NCT06069830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a personalized approach to treating a specific type of nasal lymphoma called extranodal NK/T cell lymphoma. Everyone starts with the same chemotherapy combination (Pegaspargase, Etoposide, and Dexamethasone), but after two cycles, doctors check your imaging scans and test your blood for a virus called EBV. Based on these results, your treatment plan is customized—some patients continue with radiation and additional chemotherapy, while others receive newer immunotherapy drugs (PD-1 monoclonal antibodies) combined with other treatments.
Current treatments for this rare nasal lymphoma don't work well enough for all patients, and doctors want to see if personalizing therapy based on how well patients respond early on—and whether a specific virus is still present—can improve survival and reduce unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy in the first phase (two cycles of treatment). After that, you'll have imaging scans and blood tests to check your response and virus levels. Based on these results, your doctor will assign you to one of three personalized treatment paths, which may include additional chemotherapy cycles, radiation therapy to your nasal area, and/or newer immunotherapy medications. Throughout the study, you'll have regular clinic visits, blood tests, and scans to monitor how you're responding and watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China